Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.27 AUD | -6.33% | -15.44% | -18.82% |
28/05 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
27/05 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.82% | 1.83B | |
+40.73% | 739B | |
+31.70% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.38% | 240B | |
+9.47% | 210B | |
-5.44% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- US FDA Approves Neuren Pharmaceuticals' Phase 2 Trial of Pitt Hopkins Syndrome Drug